688276 Changchun Bcht Biotechnology
- 41.69
- +1.24+3.07%
Changchun Bcht Biotechnology News
Chinese Drug Regulator Accepts BCHT Biotechnology's Marketing Application for Influenza Nasal Spray Vaccine
China's National Medical Products Administration accepted Changchun BCHT Biotechnology's (SHA:688276) marketing authorization application for its nasal spray vaccine against influenza, according to th
Baike Biotech (688276.SH): Application for marketing license for live attenuated nasal influenza vaccine was accepted
Baike Biotech (688276.SH) issued an announcement. The company recently received from the Drug Evaluation Center of the State Drug Administration...
Does Changchun BCHT Biotechnology (SHSE:688276) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
Baike Biotech (688276.SH) reported first-quarter results, net profit of 605.651 million yuan, an increase of 229.50% year-on-year
Baike Biotech (688276.SH) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Zhongtai Securities: Q1 results are about to be implemented, gradually focus on the pharmaceutical sector and individual stocks with improved Q2 performance
Zhongtai Securities said that at present, the overall market is still at a relative bottom. After experiencing a long-term correction, the pharmaceutical sector is also at multiple bottoms in terms of fundamentals, policies, and capital, and is firmly optimistic about the pharmaceutical sector market throughout the year.
Changchun BCHT Biotechnology (SHSE:688276) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Investors were disappointed with Changchun BCHT Biotechnology Co.'s (SHSE:688276) earnings, despite the strong profit numbers. We think that the market might be paying attention to some underlying fa
Changchun BCHT Biotechnology's 2023 Profit Soars 176% as Revenue Jumps 70%
Changchun BCHT Biotechnology's (SHA:688276) attributable profit surged 175.98% to 501 million yuan in 2023 from 181.5.million yuan in 2022, according to a Wednesday filing with the Shanghai bourse. Ea
Baike Biotech (688276.SH): Net profit in 2023 increased 175.98% year-on-year, and plans to pay 10 to 1.50 yuan
On March 19, Ge Longhui (688276.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 1,825 million yuan, an increase of 70.30%; net profit attributable to shareholders of listed companies of 501 million yuan, an increase of 175.98%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 493 million yuan, an increase of 195.86% year on year; and basic earnings per share of 1.21 yuan. It is proposed to distribute a cash dividend of 1.50 yuan (tax included) for every 10 shares to all shareholders.
Investors Still Waiting For A Pull Back In Changchun BCHT Biotechnology Co. (SHSE:688276)
Changchun BCHT Biotechnology Co.'s (SHSE:688276) price-to-earnings (or "P/E") ratio of 42.9x might make it look like a sell right now compared to the market in China, where around half of the compani
Baike Biotech (688276.SH) performance report: 2023 net profit of 501 million yuan, a year-on-year increase of 175.98%
On February 23, Ge Longhui (688276.SH) announced the 2023 Annual Results Report. During the reporting period, the company's total operating revenue was 1,825 million yuan, up 70.30% year on year; net profit attributable to parent company owners was 501 million yuan, up 175.98% year on year; net profit attributable to parent company owners after deducting non-recurring profit and loss was 493 million yuan, up 195.86% year on year. Affected by factors such as the decline in the birth rate of domestic newborns, domestic sales of the live attenuated chickenpox vaccine declined. The company actively promoted export work, and export sales increased; freeze-dried nasal spray influenza mitigation activities
Baike Biotech (688276.SH): Currently, the company's mRNA technology platform mainly focuses on vaccines such as the RSV vaccine
Ge Longhui, Feb. 8 | Baike Biotech (688276.SH) recently said during a survey receiving institutional investors that the company signed an investment agreement with Communication Biotech to use Communication Biotech's core advantages in mRNA vaccine research technology to help the company accelerate the construction of mRNA platform technology and expand its application; improve the intellectual property system related to mRNA vaccines; and develop mRNA delivery technology suitable for different purposes. Currently, the company's mRNA technology platform mainly focuses on vaccines such as RSV vaccines, cancer therapeutic vaccines, and HSV-2.
Baike Biotech (688276.SH): Currently, the company mainly exports chickenpox to India, Indonesia and other countries
On February 2, Ge Longhui (688276.SH) said during a survey receiving institutional investors that as the birth rate declines and the domestic market capacity for chickenpox vaccine is declining, the company will strive to stabilize the domestic market position of the chickenpox vaccine and carry out promotion work for people aged 12 and above to make up for the shortcomings in the children's market; at the same time, actively promote the export of chickenpox vaccine products, accelerate international registration and market development, and increase the number of products exported. Currently, the company mainly exports chickenpox to countries such as India and Indonesia, and is promoting product registration and export to the Middle East, Russia and other regions.
Baike Biotech (688276.SH): Plans to launch clinical trial declarations for adjuvant influenza vaccine and other products in 2024
On February 2, Ge Longhui (688276.SH) said during a survey of institutional investors that the company plans to carry out clinical trial declarations for products such as adjuvant influenza vaccine, recombinant shingles vaccine, HSV-2 mRNA vaccine, and HIB vaccine in 2024. At the same time, it is actively promoting pre-clinical research work on various R&D projects such as RSV vaccines, antibodies, and vaccines for treating Alzheimer's disease. In 2024, the company will continue to increase investment in various R&D pipelines in line with the progress of new product research and development, laying the foundation for the company's continuous development.
Baig Biotech (688276.SH): By the end of 2023, the company's shingles vaccine had effectively covered nearly one-third of the country's vaccination sites
Ge Longhui, Feb. 2: Baike Biotech (688276.SH) said during a survey of institutional investors on February 2 that according to preliminary statistics, by the end of 2023, the company's shingles vaccine had effectively covered nearly one-third of the country's vaccination sites. It is expected that in 2024, the coverage rate at vaccination sites will continue to increase.
Baike Biotech (688276.SH): Actively promoting product registration and export in the Middle East, Russia, etc.
GLONGHUI, January 26 | Baike Biotech (688276.SH) said on the investor interactive platform that in 2023, the company will actively promote product registration and export on the basis of the original international market, and the products have already been exported to India, Indonesia and other countries. At the same time, the company is actively promoting product registration and export in the Middle East, Russia and other places.
Pacific Securities: The era of high growth in the shingles market begins, and the blue ocean of big single products is expected to gradually grow
The rapidly growing Blue Ocean market for shingles is expected, and the promotion system and reimbursement system need to be improved.
Are Changchun BCHT Biotechnology Co.'s (SHSE:688276) Mixed Financials Driving The Negative Sentiment?
It is hard to get excited after looking at Changchun BCHT Biotechnology's (SHSE:688276) recent performance, when its stock has declined 15% over the past three months. We, however decided to study t
Baike Biotech (688276.SH) posted an advance increase. Net profit for 2023 is expected to reach 470 million yuan to 530 million yuan, a year-on-year increase of 158.9% to 191.95%
Baike Biotech (688276.SH) issued an announcement. The company expects to become a listed company stock in 2023...
Baig Biotech (688276.SH): Nasal spray influenza vaccine (liquid dosage form) is in the pre-NDA stage
Ge Longhui December 29 丨 Baike Biotech (688276.SH) said on the investor interactive platform that the nasal spray influenza vaccine (liquid dosage form) is in the pre-NDA stage.
Baike Biotech (688276.SH): The Hib vaccine is currently in the pre-clinical research stage
Gelonghui, December 22|Baike Biotech (688276.SH) said on the investor interactive platform that the company's Hib vaccine is currently in the pre-clinical research stage and plans to launch clinical trial applications in 2024.
Analysis
Price Target
No Data
